Novabiotics - a leading clinical-stage biotechnology company
Novabiotics about us Novabiotics clinical studies Novabiotics pipeline Novabiotics our news Novabiotics contact

NovaBiotics are delighted to announce that our latest publication is accessible from today. Teamwork focused on solutions to antimicrobial resistance with our collaborators –

Marcelo Der Torossian Torres, University of Pennsylvania

Cesar de la Fuente, University of Pennsylvania

Alfredo Angeles-Boza, University of Connecticut

Searle Aichelle Duay, University of Connecticut

Maren von Kockritz-Blickwede, University of Hannover

“Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy”. Part of a series on “Bridging the Gap between Discovery and Clinical Development for Antimicrobial Peptides”. Antimicrobial peptides are a new class of therapy with a great deal of potential but have to be developed using appropriate methodologies. Read this special edition of Frontiers in Cellular & Infection Microbiology – Clinical Microbiology – to find out more.

https://tinyurl.com/yb82p8oz